bay2395840
Peripheral Neuropathic Pain
BayerPhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
31 Active assets in the Peripheral Neuropathic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin University of Rochester | Phase 4 | A |
LIDOCAINE University of Utah | Phase 4 | BBB |
Nabiximols VA Office of Research and Development | Phase 3 | BBB |
Eloxatin Tanta University | Phase 3 | BBB |
LIDOCAINE University Health Network, Toronto | Phase 3 | BB |
View all 50 →
Same molecule, other indications
bay2395840 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →